insights_auto
Why is CRSP up 3.45%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
$57.34
arrow_upward
+3.45%(+1.91) 1D
$58.73
arrow_upward
+2.42% (+1.39)todayPre-market
Closed: Oct 5, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$55.21
High
$57.46
Low
$54.01
Mkt. cap
5.54B
Avg. vol.
1.54M
Volume
21.94K
52-wk high
$78.48
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
Open
$55.21
High
$57.46
Low
$54.01
Mkt. cap
5.54B
Avg. vol.
1.54M
Volume
21.94K
52-wk high
$78.48
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
News stories
From web sources and news partners
Benzinga
·
3 hours ago
Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’
Zacks
·
22 hours ago
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
AD HOC NEWS
·
1 day ago
CRISPR Therapeutics stock gets a November gene editing data date ?????????? no
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com